Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CM338 injection in IgA nephropathy
CTR20230619Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM338 in IgA nephropathy (IgAN), sponsored by Keymed Biosciences. Started Jul 2023; status: active.
02
Drugs
CM338
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20230619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230619.